^
    CANCER:

    Urothelial Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    atezolizumab
    		0
    PD-L1 inhibitor
    durvalumab
    avelumab
    PD-L1 inhibitor
    pembrolizumab
    nivolumab
    toripalimab-tpzi
    		1
    PD1 inhibitor
    tislelizumab
    PF-06801591
    retifanlimab-dlwr
    zimberelimab
    PD1 inhibitor
    cisplatin
    cisplatin + gemcitabine
    		2
    DNA synthesis inhibitor
    gemcitabine
    mitomycin urothelial gel
    gemcitabine-releasing intravesical system
    BAY 1163877
    infigratinib
    pemigatinib
    ABSK091
    		3
    FGFR inhibitor
    ARQ 087
    futibatinib
    Debio 1347
    AZ8010
    FGFR inhibitor
    5-fluorouracil
    		4
    Thymidylate synthase inhibitor
    5-fluorouracil
    capecitabine
    5
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    6
    IFNα stimulant
    nadofaragene firadenovec-vncg
    olaparib
    		7
    PARP inhibitor
    rucaparib
    PARP inhibitor
    8
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    9
    mTOR inhibitor
    everolimus
    10
    FGFR inhibitor, PD-L1 inhibitor
    atezolizumab + BAY 1163877
    durvalumab + ABSK091
    11
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    SHR-A1811
    12
    PD1 inhibitor, PI3Kγ inhibitor
    nivolumab + IPI-549
    13
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    14
    IL-15 superagonist
    inbakicept
    15
    Apoptosis stimulant
    Alpha1H
    16
    Reactive oxygen species stimulant
    AU-011
    pazopanib
    		17
    Multi-tyrosine kinase inhibitor
    anlotinib
    ponatinib
    18
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    B-701
    		19
    FGFR3 inhibitor
    TYRA-300
    FGFR3 inhibitor
    20
    HER2 inhibitor
    trastuzumab-pkrb
    trastuzumab
    21
    Tubulin polymerization promoter
    carboplatin
    22
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    23
    PD1 inhibitor, EphB4 inhibitor
    pembrolizumab + sEphB4-HSA
    24
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    25
    DNA PK inhibitor
    NU7441
    M3814
    26
    PD1 inhibitor, ICOS agonist
    pembrolizumab + GSK3359609
    27
    PI3K inhibitor
    AN2025
    28
    IL-6R antagonist, PD-L1 inhibitor
    atezolizumab + tocilizumab
    29
    CDC7 kinase inhibitor
    LY3143921
    30
    VEGFR-2 inhibitor
    ramucirumab
    31
    MEK inhibitor
    trametinib
    32
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    33
    Nectin-4-targeted antibody-drug conjugate, Microtubule inhibitor
    enfortumab vedotin-ejfv
    34
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    35
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    36
    Nectin-4-targeted antibody-drug conjugate, PD1 inhibitor, Microtubule inhibitor
    pembrolizumab + enfortumab vedotin-ejfv
    37
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    38
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    39
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    gemcitabine + ifosfamide + pegylated liposomal doxorubicin
    cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
    40
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    gemcitabine + paclitaxel
    cisplatin + paclitaxel
    41
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + etoposide IV
    42
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    43
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    44
    Nectin-4-targeted peptide-drug conjugate, Microtubule inhibitor
    BT8009
    45
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    disitamab vedotin
    ado-trastuzumab emtansine
    46
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, PD1 inhibitor, FGFR4 inhibitor
    erdafitinib + JNJ-63723283
    47
    Cell death stimulant, GM-CSF agonist
    CG0070
    48
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    49
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    toripalimab-tpzi + disitamab vedotin
    tislelizumab + disitamab vedotin
    50
    PD-L1 inhibitor, PD1 inhibitor
    durvalumab + MEDI0680
    51
    PD1 inhibitor, GDF15 inhibitor
    nivolumab + CTL-002
    52
    CD137 agonist, HER2 inhibitor
    PRS-343
    53
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    54
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    55
    PD-L1 inhibitor, mTOR inhibitor, mTORC2 inhibitor
    durvalumab + AZD2014
    56
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    nivolumab + fam-trastuzumab deruxtecan-nxki
    57
    PD-L1 inhibitor, CD47 inhibitor
    atezolizumab + GS-4721
    58
    FGFR3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AMB302
    59
    KRAS G12C inhibitor, mTORC1 inhibitor
    adagrasib + nanoparticle albumin-bound rapamycin
    sotorasib + nanoparticle albumin-bound rapamycin
    60
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    61
    CA6-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR566658
    62
    FGFR3-targeted antibody-drug conjugate, Microtubule inhibitor
    LY3076226
    63
    DNA synthesis inhibitor, Cytidine deaminase inhibitor, DNA methylation inhibitor
    gemcitabine + EPI01
    64
    EZH2 inhibitor
    GSK2816126
    65
    EGFR inhibitor
    cetuximab
    66
    Tyrosine kinase inhibitor
    PD173074
    67
    ATR inhibitor
    M6620
    68
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    69
    FGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + infigratinib
    70
    Integrin beta-6 -targeted antibody-drug conjugate, Microtubule inhibitor
    SGN-B6A
    71
    WDR5 inhibitor
    OICR-9429
    72
    WEE1 inhibitor
    AZD1775
    73
    MAT2A inhibitor
    IDE397
    74
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    75
    BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
    OTX015
    76
    PIK3C3 inhibitor, FGFR inhibitor
    MPT0L145
    77
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    78
    DDX5 degrader
    FL118
    79
    KRAS G12C inhibitor
    sotorasib
    80
    PD-L1 inhibitor, NK cell stimulant
    avelumab + CYNK-101
    81
    EGFR inhibitor, IFN stimulant, TROP-2 inhibitor
    ABN202
    82
    Immunotherapy
    Immunotherapy
    FOLFOX
    		83
    Chemotherapy
    ddMVAC
    EP
    GC
    84
    CTLA4 inhibitor
    CTLA4 inhibitor
    85
    FGFR2 inhibitor
    FGFR2 inhibitor
    No biomarker
    PD-L1 expression
    PD-L1 overexpression
    TMB-H + PD-L1 expression
    DDR + PD-L1 expression
    PD-L1 elevation
    PD-L1 negative
    PD-L1 underexpression
    PD-L1 expression + T-cell gene signature
    FGFR3 mutation
    FGFR3 fusion
    FGFR3 S249C
    FGFR3 G380R
    FGFR3 Y375C
    FGFR3 Y373C
    FGFR3 expression
    FGFR3 overexpression
    FGFR3 R248C
    FGFR3 G370C
    FGFR3 rearrangement
    FGFR3 A393E
    FGFR3 V443M
    FGFR3 S247C
    FGFR3 K508M
    FGFR3 V443L
    FGFR3 L496V
    FGFR mutation
    FGFR expression
    FGFR overexpression
    FGFR fusion
    HER-2 positive
    HER-2 overexpression
    HER-2 mutation
    HER-2 amplification
    HER-2 expression
    ERCC2 Y24C
    ERCC2 E606Q
    ERCC2 D609G
    ERCC2 G665A
    ERCC2 V242F
    ERCC2 P463L
    ERCC2 E606G
    ERCC2 N238S
    ERCC2 mutation
    ERCC2 D609E
    HRAS G13R
    HRAS mutation
    HRAS G12S
    HRAS H27_28fs*
    HRAS Q61R
    HRAS G12C
    HRAS Q61
    TMB-H
    FGFR2 fusion
    FGFR2 A391E
    FGFR2 mutation
    TMB-H + DDR
    FGFR2 underexpression
    FGFR3-TACC3 fusion
    FGFR1 amplification
    FGFR1 overexpression
    ERBB3 G284R
    ERBB3 V104M
    ERBB3 R103G
    FGFR1 expression
    ERBB3 mutation
    FGFR1 mutation
    FGFR3-TACC3 F17T8
    FGFR3-TACC3 fusion + FGFR3 V555M
    ERBB3 expression
    TSC1 mutation
    TSC1 1907_1908del
    TSC1 deletion
    PD-1 expression
    CD8 expression
    BRCA1 N1018fs*8
    MTOR E2014K
    CD8 overexpression
    PIK3CA mutation
    TMB-H + PD-L1 negative
    PD-L1 expression + TMB-H
    BRCA2 mutation
    MSH2 mutation
    BRCA2 L557*
    MTOR E2419K
    BRCA1 underexpression
    MSH2 deletion
    PIK3CA M1043I
    PIK3CA mutation + MSI-L/dMMR
    EGFR amplification
    ATM mutation
    MSI-H/dMMR
    BAP1 mutation
    FANCF mutation
    PALB2 mutation
    BRIP1 mutation
    TP53 mutation
    NECTIN4 expression
    TET1 mutation
    FGFR3-BAIAP2L1 fusion
    RB1 mutation
    BIRC5 expression
    RB1 mutation + TP53 mutation
    RB1 mutation + PD-L1 expression
    PBRM1 mutation
    FGF mutation
    FGF10 amplification
    TGFB1 underexpression
    FGFR2-BICC1 fusion
    FGFR2-CASP7 fusion
    PTEN expression
    IFNA1 expression
    IFNG expression
    TERT promoter mutation
    CXCL13 mutation + ARID1A mutation
    PCSK9 underexpression
    CXCL13 expression
    RNF43 mutation
    KMT2C mutation
    TLR4-L
    ARID1A mutation
    EPHB2 expression
    KIFC1 expression
    DRD
    CREBBP mutation
    CD93 underexpression
    ERCC1 underexpression
    CALCR overexpression
    MTAP deletion
    CTLA4 underexpression
    GNG4 overexpression
    CXCR3 overexpression
    ITGAX underexpression
    APH1A overexpression
    NOTCH3 underexpression
    VTCN1 overexpression
    SAAL1 overexpression
    EFNB2 expression
    CD163 overexpression
    CD68 overexpression
    B2M overexpression
    KDM6A mutation
    PD-L1 overexpression + APOBEC3B overexpression
    NT5E underexpression
    TMB-H + MLL2 mutation
    TMB-H + KDM6A mutation
    TMB-H + TERT promoter mutation
    TMB-H + PIK3CA mutation
    LAMP3 expression
    CXCL10 expression
    CXCL10 overexpression + LAMP3 overexpression
    FGFR mutation + PD-L1 expression
    TP53 mutation + MDM2 mutation
    SLC35A2 overexpression
    GBP5 expression
    CXCL9 expression
    ITIH5 overexpression
    SRRM4 overexpression
    TMEM72 underexpression
    NPHS1 underexpression
    CCDC69 overexpression
    MLH1 mutation
    NRF1-BRAF fusion
    MSH6 deletion
    MSH4 L359I
    TMB-H + RB1 mutation + PD-L1 underexpression
    ATM deletion
    NECTIN4 underexpression
    ERBB3 mutation + TMB-H
    MTAP mutation
    APOBEC mutagenesis
    High MHC-II signature
    IFNG gene signature overexpression
    12-CK gene signature
    SBS5 signature
    IFNG gene signature
    DDR
    IFNG 4-genes signature
    HER-2 mutation + TMB-H
    KRAS mutation
    CDKN2A mutation
    NOTCH1 mutation + MSI-L/dMMR
    ELF3 mutation + MSI-L/dMMR
    ELF3 mutation + TMB-L + MSI-L/dMMR
    LYPD3 expression
    HLA-A*03
    CCNE1 amplification
    NOTCH1 mutation + TMB-L + MSI-L/dMMR
    HYAL4 V1
    WDR5 overexpression
    ITGB6 expression
    OXCT1 expression
    CXCL8 elevation
    PTEN deletion + KRAS G12C
    TROP2 positive
    PD-L1 expression + REV3L overexpression
    High NLR
    PD-L1 expression + MTOR overexpression
    TUBA1C overexpression
    YTHDC1 underexpression
    KRAS G12C
    PD-1-L + PD-L1 elevation
    FGF19 mutation
    FGF4 mutation
    H19 overexpression
    KRT20 overexpression
    TMB-H + CDKN2B mutation
    TMB-L + RB1 mutation
    FGF3 mutation
    COL6A1 overexpression
    HLA-DQB1*03:01
    GSDMB expression
    MTAP mutation + CDKN2A mutation
    GPC1 overexpression
    MAST4 mutation
    CA6 expression
    CDKN2B mutation
    ACTA2 underexpression
    FGFR2 underexpression + FGFR3 overexpression
    FGFR2 underexpression + FGFR3 mutation
    TDO2 overexpression
    RAD52 underexpression
    IL20RB overexpression